TRADING UPDATES: Minoan in debt talks; Sealand perplexed by share rise
6th Jan 2025 21:34
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
Graft Polymer (UK) PLC - London-based developer and producer of alloyed polymers, biological supplements and drug delivery systems - Selects drug discovery solutions provider Eurofins Discovery to carry out initial testing for its co-lead aminoindane series, to begin immediately. First announced in July, the programme is under joint development with Awakn Life Sciences Corp and seeks to develop next-generation medicines targeting trauma-related mental health conditions like Post-Traumatic Stress Disorder. The condition affects about 20 million adults in the US, UK, and key European markets, Graft Polymer notes. Tests will assess the potential of Graft's aminoindane series for serotonin, dopamine and noradrenaline reuptake inhibition. Selection marks a significant milestone, the company says, and follows its August announcement that it filed a new provisional patent in the US after Awakn "identified two aminoindane chemical series as co-leads for further development". Read More
(Alliance News) - Graft Polymer UK PLC on Friday it was confident in its strategy as it reported a narrowed interim loss. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of London-listed company director and manager changes announced in August so far and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
Graft Polymer (UK) PLC - London-based developer and producer of alloyed polymers, biological supplements and drug delivery systems - Files US patent applications for the treatment of substance abuse disorders and mental health disorders using depot drug delivery systems. Graft Polymer says the patent applications aim to leverage its biopolymer expertise in mental health therapy and the treatment of addiction. It is seeking to develop its intellectual property portfolio as part of its new focus on the healthcare industry following the disposal of its industrial plastic manufacturing unit, Graft Polymer DOO. Read More
Graft Polymer (UK) PLC - London-based biopolymer drug delivery systems development company - Says 2.17 billion new ordinary shares, including 1.8 billion placing shares have been admitting to trading on the main market of the London Stock Exchange and to the standard segment of the Financial Conduct Authority's Official List. Total share capital after admission is 2.30 billion. As company holds no ordinary shares in treasury the total number of ordinary shares and voting rights is 2.30 billion. Read More
(Alliance News) - Shares in Graft Polymer UK PLC nearly doubled on Friday after it said it drug delivery systems would be a focus area after concluding the first phase of its operational review. Read More
(Alliance News) - Shares in Graft Polymer (UK) PLC rose on Friday, as the company announced the filing of a patent for its proprietary technology, which it said addresses a significant unmet need in the treatment of mental health disorders. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
Graft Polymer (UK) PLC - London-based developer and producer of polymer modification and drug delivery systems - Announces the grant of patent P-202400066, which it says will further strengthen its IP portfolio. "The disclosed dual hydrogel multi-crosslinking haemostatic composition offers a groundbreaking solution for emergency haemostasis by amalgamating two distinct gels, each possessing unique cross-linking mechanisms and bioactive components," it says. Chief Executive Officer Anthony Tennyson says: "The global emergency hemostasis products market is significant and growing, and the grant of this patent underscores the potential of our Graft Bio division. With our enhanced hemostasis IP portfolio, we are well-equipped to address the evolving needs of healthcare professionals and patients in this segment. Concurrently, we are actively pursuing our previously announced review of the company's operations to identify additional opportunities for growth." Read More
Graft Polymer (UK) PLC - London-based developer and producer of polymer modification and drug delivery systems - Disposes of Slovenia entity, Graft Polymer doo, to a private consortium in Slovenia for nominal consideration. "The directors believe that the company's Graft Bio division represents significant value to investors based primarily on the revenue generating possibilities of Graft's intellectual property, intangible assets and research & development contracts," it says. Read More
(Alliance News) - Graft Polymer (UK) PLC on Thursday said its chief executive officer has stepped down, naming a successor with immediate effect. Read More
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More